AZRX AzurRx BioPharma, Inc.

3.97
0  -1%
Previous Close 4.00
Open 4.02
Price To book 11.98
Market Cap 38.24M
Shares 9,631,000
Volume 6,600
Short Ratio 0.16
Av. Daily Volume 15,111

SEC filingsSee all SEC filings

  1. D - Notice of Exempt Offering of Securities 17774841
  2. 8-K - Current report 17757140
  3. 8-K - Current report 17757112
  4. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17730567
  5. 8-K - Current report 17678887

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Announced December 21, 2016 that Phase 2 enrollment has commenced. Trial completion due 3Q 2017.
MS1819-SD
Exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis (CP)

SEC Filings

  1. D - Notice of Exempt Offering of Securities 17774841
  2. 8-K - Current report 17757140
  3. 8-K - Current report 17757112
  4. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17730567
  5. 8-K - Current report 17678887
  6. 8-K - Current report 17656136
  7. 10-Q - Quarterly report (Sections 13 or 15(d)) 162017524
  8. 8-K - Current report 161937340
  9. CT ORDER - Confidential treatment order 161934571
  10. 424B4 - Prospectus (Rule 424(b)(4)) 161933871